PDL1 Antibody [1F11] | RF16037

PDL1 Antibody [1F11] | RF16037 | Gentaur UK, US & Europe Distribution

Host: Mouse

Reactivity: Human

Homology: N/A

Immunogen: PD-L1 antibody was raised against the extracellular domain of human PD-L1.

Research Area: Immunology

Tested Application: E, WB, IHC-P, ICC, IF

Application: PD-L1 antibody can be used for detection of PD-L1 by Western blot at 1 - 2 μg/mL. Antibody can also be used for immunohistochemistry starting at 2 - μg/mL. For immunofluorescence start at 5 μg/mL.
Antibody validated: Western Blot in human samples; Immunohistochemistry in human samples; Immunocytochemistry in human samples and Immunofluorescence in human samples. All other applications and species not yet tested.

Specificiy: N/A

Positive Control 1: Cat. No. 1340 - Human Stomach Carcinoma Tissue Lysate

Positive Control 2: Cat. No. 1315 - Human Tonsil Tissue

Positive Control 3: N/A

Positive Control 4: N/A

Positive Control 5: N/A

Positive Control 6: N/A

Molecular Weight: Predicted: 32 kDa
Observed: 45 kDa

Validation: N/A

Isoform: N/A

Purification: PD-L1 Antibody is supplied as protein A purified IgG1.

Clonality: Monoclonal

Clone: 1F11

Isotype: IgG1

Conjugate: Unconjugated

Physical State: Liquid

Buffer: PD-L1 Antibody is supplied in PBS containing 0.02% sodium azide and 50% glycerol.

Concentration: 1 mg/mL

Storage Condition: PD-L1 antibody can be stored at 4˚C for three months and -20˚C, stable for up to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.

Alternate Name: PD-L1 Antibody: Programmed cell death 1 ligand-1, programmed death ligand 1, PDL1, PDL-1, B7-H1

User Note: Optimal dilutions for each application to be determined by the researcher.

BACKGROUND: PD-L1 Antibody: Cell-mediated immune responses are initiated by T lymphocytes that are themselves stimulated by cognate peptides bound to MHC molecules on antigen-presenting cells (APC) (1) . T-cell activation is generally self-limited as activated T cells express receptors such as PD-1 (also known as PDCD-1) that mediate inhibitory signals from the APC (2) . PD-1 can bind two different but related ligands, PD-L1 and PD-L2. PD-L1 is a B7-related protein that inhibits cell-mediated immune responses by reducing the secretion of IL-2 and IL-10 from memory T cells (3) . This suggests that PD-L1 may be useful in reducing allogenic CD4+ memory T-cell responses to endothelial cells, thereby reducing the likelihood of host immune responses to allografts. PD-L1 also functions as an immune checkpoint protein, and multiple anti-PD-L1 antibodies are currently in phase II and III clinical trials, with one antibody already approved for the treatment of cancer (4) .